GO:0002355 detection of tumor cell: Immune Surveillance Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002355 detection of tumor cell is defined by QuickGO as the series of events in which a stimulus from a tumor cell is received and converted into a molecular signal.
• This biological process is a critical first step in immune surveillance, enabling the host to sense malignant or premalignant cells before they become clinically apparent.
• Detection of tumor cell underlies early cancer diagnosis, including cell-free DNA fragmentomics for malignant peripheral nerve sheath tumors.
• Tumor cell detection is relevant to both benign mimics and malignant tumors, as seen in giant cell-rich tumors of bone and ovarian follicle cysts.
• Key genes and proteins involved include ALDH1, immune cell markers, and tumor-derived DNA fragments that serve as detection signals.
• CRISPR knockout, knock-in, and overexpression models are essential to dissect the molecular machinery of tumor cell detection.
Description
Detection of tumor cell (GO:0002355) is a biological process defined by QuickGO as the series of events in which a stimulus from a tumor cell is received and converted into a molecular signal. This process represents the earliest step in immune recognition of malignancy, where the host immune system or diagnostic assays sense tumor-derived cues. Understanding this process is fundamental for cancer immunology, early diagnosis, and the development of targeted therapies. The detection of tumor cells is not a single event but a coordinated series of molecular interactions that can involve cell-free DNA fragmentomics, immune cell populations, and tumor stem cell markers. In neurofibromatosis 1, the detection of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumors relies on histopathologic evaluation and molecular signals. Similarly, the establishment of recurrent malignant peripheral nerve sheath tumor cell lines such as RsNF provides tools to study how tumor cells are detected and characterized. These examples highlight the translational importance of GO:0002355 in oncology and pathology.
detection of tumor cell At A Glance
| GO ID | GO:0002355 |
|---|---|
| GO term | detection of tumor cell |
| Ontology | biological_process |
| Synonym | none |
| Major function | Receiving a stimulus from a tumor cell and converting it into a molecular signal |
| Definition source | QuickGO |
| Related disease context | Cancer, neurofibromatosis 1, malignant peripheral nerve sheath tumors, giant cell-rich tumors of bone |
| Key experimental models | Cell lines (e.g., RsNF), cell-free DNA fragmentomics, histopathologic evaluation |
| Research relevance | Early cancer detection, immune surveillance, tumor microenvironment studies |
What Is GO:0002355?
In our own words, detection of tumor cell (GO:0002355) is the biological process by which a stimulus originating from a tumor cell is received by a sensor or receptor system and converted into a molecular signal. This process is the initial step in a cascade that can lead to immune activation, diagnostic identification, or cellular responses. It encompasses the recognition of tumor-derived molecules, such as cell-free DNA fragments, surface markers, or secreted factors, and the subsequent intracellular signaling that translates this recognition into a measurable biological output.
Why Is detection of tumor cell Important in Cell Biology?
Detection of tumor cell (GO:0002355) is critically important because it represents the first checkpoint in immune surveillance and early cancer diagnosis. Without efficient detection, malignant cells can evade immune recognition and progress to advanced stages. This process is directly linked to clinical applications such as early detection of malignant and premalignant peripheral nerve tumors using cell-free DNA fragmentomics. It also informs histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumors in neurofibromatosis 1 patients. Furthermore, understanding tumor cell detection helps differentiate benign mimics from malignant tumors, as seen in large ovarian follicle cysts and giant cell-rich tumors of bone. The expression of tumor stem cell markers like ALDH1 in benign epithelial odontogenic lesions further illustrates the need to distinguish detection signals in benign versus malignant contexts. Immune cell populations in cutaneous neurofibromas also play a role in tumor cell detection and surveillance.
• Enables early detection of malignant and premalignant peripheral nerve tumors through cell-free DNA fragmentomics.
• Facilitates histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumors.
• Helps distinguish benign mimics from malignant tumors, such as in giant cell-rich tumors of bone and ovarian follicle cysts.
• Involves tumor stem cell markers like ALDH1, which are expressed in benign epithelial odontogenic lesions and can inform detection strategies.
• Relies on immune cell populations in cutaneous neurofibromas, linking detection to the tumor microenvironment.
• Provides a basis for establishing and characterizing recurrent malignant peripheral nerve sheath tumor cell lines for research.
• Supports clinical management of hand tumors by improving diagnostic accuracy.
• Underpins the development of CRISPR-based models to study tumor cell recognition mechanisms.
What Happens During detection of tumor cell?
Receipt of Tumor Cell Stimulus
In simple terms: The body first senses that a tumor cell is present.
The process begins when a stimulus from a tumor cell is received by a sensor system. This can involve tumor-derived cell-free DNA fragments that are detected in bodily fluids, as demonstrated in early detection of malignant and premalignant peripheral nerve tumors using cell-free DNA fragmentomics. In histopathologic evaluation, the stimulus may be morphological or molecular features of atypical neurofibromatous tumors. The receipt of this stimulus is the initial event that triggers downstream signaling.
Conversion into a Molecular Signal
In simple terms: The initial detection is turned into a chemical message inside cells.
Once the tumor cell stimulus is received, it is converted into a molecular signal. This conversion can involve immune cell populations that recognize tumor antigens, as characterized in cutaneous neurofibromas of neurofibromatosis 1. The molecular signal may include cytokine release, receptor phosphorylation, or changes in gene expression. In the context of giant cell-rich tumors of bone, the conversion may involve signaling pathways that distinguish neoplastic from reactive processes.
Amplification and Integration of the Signal
In simple terms: The signal is boosted and combined with other information.
The molecular signal is amplified and integrated with other cellular cues. This step can involve tumor stem cell markers such as aldehyde dehydrogenase 1 (ALDH1), which are expressed in benign epithelial odontogenic lesions and may modulate detection thresholds. Integration may also involve immune cell crosstalk in the tumor microenvironment, as seen in cutaneous neurofibromas. The amplified signal can lead to a measurable output, such as a diagnostic readout or an immune response.
Downstream Cellular Responses
In simple terms: The cell reacts to the detected tumor signal.
The converted and integrated signal triggers downstream cellular responses. These can include immune activation, apoptosis, or diagnostic identification. For example, the establishment and characterization of a recurrent malignant peripheral nerve sheath tumor cell line (RsNF) allows researchers to study these downstream responses in vitro. In clinical settings, the response may manifest as histopathologic changes that confirm the presence of a tumor, as seen in atypical neurofibromatous tumors. The management of hand tumors also relies on accurate detection and subsequent clinical decision-making.
Resolution and Diagnostic Output
In simple terms: The detection process ends with a clear result, such as a diagnosis.
The final stage of detection of tumor cell involves resolution of the signal into a diagnostic or biological output. This can be a confirmed diagnosis of a malignant or premalignant tumor, as achieved through cell-free DNA fragmentomics. It can also be the differentiation of a benign mimic from a malignant tumor, such as in large ovarian follicle cysts. The output may guide clinical management, including surgical or therapeutic decisions for hand tumors.
Key Genes Involved in GO:0002355 detection of tumor cell
The following genes and proteins are involved in the detection of tumor cell (GO:0002355), based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ALDH1 | Tumor stem cell marker | Expressed in benign epithelial odontogenic lesions; potential detection marker |
| CD45 | Immune cell marker | Characterizes immune cell populations in cutaneous neurofibromas |
| CD3 | T cell marker | Used to identify T cell populations in neurofibromas |
| CD20 | B cell marker | Used to identify B cell populations in neurofibromas |
| CD68 | Macrophage marker | Detects macrophage infiltration in tumor microenvironment |
| NF1 | Tumor suppressor | Mutations lead to neurofibromatosis 1 and atypical neurofibromatous tumors |
| TP53 | Tumor suppressor | Frequently altered in malignant peripheral nerve sheath tumors |
| CDKN2A | Cell cycle inhibitor | Deletion associated with transformation of neurofibromas |
| H3F3A | Histone variant | Mutated in giant cell-rich tumors of bone |
| H3F3B | Histone variant | Mutated in giant cell-rich tumors of bone |
| FOXL2 | Transcription factor | Relevant to ovarian follicle cysts and granulosa cell tumors |
| CTNNB1 | Beta-catenin | Involved in odontogenic lesion signaling |
| KRAS | Oncogene | Potential driver in malignant peripheral nerve sheath tumors |
| EGFR | Receptor tyrosine kinase | Overexpressed in some malignant peripheral nerve sheath tumors |
| VIM | Vimentin | Mesenchymal marker used in tumor cell characterization |
| SOX10 | Neural crest marker | Expressed in malignant peripheral nerve sheath tumors |
| S100B | Neural crest marker | Used in histopathologic evaluation of neurofibromatous tumors |
How Is detection of tumor cell Regulated?
The detection of tumor cell (GO:0002355) is regulated at multiple levels. Immune cell populations, such as T cells, B cells, and macrophages, modulate the sensitivity and specificity of tumor cell detection in the microenvironment. Tumor stem cell markers like ALDH1 can influence detection thresholds in benign and malignant lesions. Genetic alterations in NF1, CDKN2A, and TP53 regulate the transition from benign neurofibromas to malignant peripheral nerve sheath tumors, thereby affecting the detectability of tumor cells. Additionally, cell-free DNA fragmentomics provides a circulating biomarker that reflects tumor burden and can be used to monitor detection dynamics.
detection of tumor cell and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NF1 | Neurofibromatosis 1 and malignant peripheral nerve sheath tumors | NF1 knockout cell line or mouse model |
| CDKN2A | Transformation of neurofibromas to malignant peripheral nerve sheath tumors | CDKN2A knockout in RsNF cells |
| TP53 | Malignant peripheral nerve sheath tumor progression | TP53 point mutation knock-in |
| H3F3A | Giant cell-rich tumors of bone | H3F3A mutant overexpression |
| ALDH1 | Benign epithelial odontogenic lesions | ALDH1 knockout or overexpression in odontogenic cells |
Neurofibromatosis 1 and Malignant Peripheral Nerve Sheath Tumors
In neurofibromatosis 1, the detection of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumors is a critical clinical challenge. Histopathologic evaluation remains the cornerstone for detecting these tumors, and consensus criteria help standardize diagnosis. Cell-free DNA fragmentomics has emerged as a promising approach for early detection of malignant and premalignant peripheral nerve tumors, enabling non-invasive monitoring. The establishment of recurrent malignant peripheral nerve sheath tumor cell lines, such as RsNF, provides valuable models to study detection mechanisms and test therapeutic interventions. Immune cell populations in cutaneous neurofibromas also contribute to the detection process and may influence tumor progression.
Giant Cell-Rich Tumors of Bone
Giant cell-rich tumors of bone represent a spectrum of lesions where detection of tumor cells is essential for accurate diagnosis. These tumors can be benign or malignant, and histopathologic evaluation, including the identification of H3F3A and H3F3B mutations, aids in distinguishing them. The detection process involves recognizing specific molecular signals that differentiate neoplastic from reactive giant cell lesions. Understanding GO:0002355 in this context can improve diagnostic accuracy and guide clinical management.
Ovarian Follicle Cysts and Granulosa Cell Tumors
Large ovarian follicle cysts can mimic cystic adult granulosa cell tumors, making the detection of tumor cells challenging. Accurate detection requires careful histopathologic evaluation and may involve markers such as FOXL2. The ability to distinguish benign cysts from malignant tumors is crucial for avoiding unnecessary surgery and ensuring appropriate treatment. Research into GO:0002355 can help identify molecular signals that differentiate these entities.
Benign Epithelial Odontogenic Lesions
Benign epithelial odontogenic lesions can express tumor stem cell markers like ALDH1, which may complicate the detection of malignant transformation. The detection of tumor cells in these lesions requires careful interpretation of marker expression and histopathologic features. Understanding the molecular signals involved in GO:0002355 can aid in distinguishing benign from malignant odontogenic lesions and guide clinical follow-up.
From detection of tumor cell-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does NF1 loss enhance tumor cell detection by immune cells? | NF1 knockout cell line co-cultured with immune cells |
| How does CDKN2A deletion affect detection of malignant peripheral nerve sheath tumor cells? | CDKN2A knockout in RsNF cell line |
| Can point mutations in TP53 alter tumor cell detection signals? | TP53 point mutation knock-in in neurofibroma cells |
| Does ALDH1 overexpression increase detection in odontogenic lesions? | ALDH1 overexpression in benign odontogenic cell line |
| What is the role of H3F3A mutation in giant cell tumor detection? | H3F3A mutant knock-in in bone stromal cells |
| How do immune cell populations detect cutaneous neurofibroma cells? | Co-culture of neurofibroma cells with T cells, B cells, and macrophages |
How to Study the detection of tumor cell Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Cell-free DNA fragmentomics | Fragmentation patterns of circulating DNA | Early detection of malignant and premalignant peripheral nerve tumors |
| Histopathologic evaluation | Microscopic features of tissue sections | Diagnosis of atypical neurofibromatous tumors and giant cell-rich tumors |
| Immunohistochemistry | Protein expression in tissue sections | Detection of ALDH1 and immune cell markers |
| Cell line establishment | Growth and characterization of tumor cells | Studying recurrent malignant peripheral nerve sheath tumors |
| Flow cytometry | Immune cell populations | Characterizing cutaneous neurofibromas |
| DNA sequencing | Genetic mutations | Identifying NF1, CDKN2A, TP53 alterations |
| CRISPR knockout | Gene function | Dissecting detection pathways |
| RNA-seq | Gene expression profiles | Identifying detection-associated signatures |
Cell-Free DNA Fragmentomics
Cell-free DNA fragmentomics is a method that analyzes the fragmentation patterns of circulating DNA to detect tumor-derived signals. This approach has been used for early detection of malignant and premalignant peripheral nerve tumors, demonstrating its utility in GO:0002355 research. It measures the size distribution and genomic coverage of cell-free DNA, which can reflect the presence of tumor cells.
Histopathologic Evaluation
Histopathologic evaluation involves microscopic examination of tissue sections to identify tumor cells and their characteristics. This method is essential for detecting atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumors. It can also distinguish benign mimics from malignant tumors, such as in giant cell-rich tumors of bone and ovarian follicle cysts.
Immunohistochemistry
Immunohistochemistry uses antibodies to detect specific proteins in tissue sections. It is used to identify tumor stem cell markers like ALDH1 in benign epithelial odontogenic lesions and immune cell populations in cutaneous neurofibromas. This method helps visualize the molecular signals involved in tumor cell detection.
Cell Line Establishment and Characterization
Establishing and characterizing tumor cell lines, such as the recurrent malignant peripheral nerve sheath tumor cell line RsNF, allows researchers to study detection mechanisms in vitro. These models can be used for functional assays, drug testing, and CRISPR-based editing to dissect GO:0002355 pathways.
How CRISPR Can Be Used to Study GO:0002355 detection of tumor cell
Knockout
CRISPR knockout is used to delete genes such as NF1, CDKN2A, or TP53 to study their role in detection of tumor cell (GO:0002355). For example, knocking out NF1 in cell lines can mimic neurofibromatosis 1 and reveal how loss of this tumor suppressor affects the detection of malignant peripheral nerve sheath tumor cells. Knockout of ALDH1 can test its contribution to detection in odontogenic lesions.
Point Mutation
CRISPR point mutation introduces specific nucleotide changes to model disease-associated variants. For instance, point mutations in TP53 or H3F3A can be introduced to study their impact on tumor cell detection signals. This approach allows precise interrogation of how single amino acid changes alter the detection process.
Knock-in
CRISPR knock-in can insert reporter genes or tags into endogenous loci to visualize and quantify detection events. For example, knocking in a fluorescent reporter downstream of a tumor cell detection-responsive promoter can enable live-cell imaging of GO:0002355. Knock-in of mutant H3F3A can model giant cell-rich tumors of bone.
Overexpression
CRISPR overexpression, often achieved by knock-in of a strong promoter or cDNA, is used to study gain-of-function effects. Overexpressing ALDH1 in benign odontogenic cells can test whether it enhances detection signals. Overexpression of oncogenes like KRAS or EGFR can model malignant peripheral nerve sheath tumors and assess their detectability.
How EDITGENE Supports detection of tumor cell Research
Researchers studying detection of tumor cell-related genes often need to determine whether a candidate gene is causally involved in the recognition and signaling of tumor-derived stimuli. EDITGENE provides a comprehensive suite of CRISPR services to enable these investigations, from knockout to overexpression and library screening.
Contact EDITGENE today to design your custom CRISPR model for detection of tumor cell research.
Frequently Asked Questions About detection of tumor cell
What is GO:0002355 detection of tumor cell?
GO:0002355 is a Gene Ontology biological process term defined as the series of events in which a stimulus from a tumor cell is received and converted into a molecular signal.
What genes are involved in detection of tumor cell?
Genes such as NF1, CDKN2A, TP53, ALDH1, and immune cell markers like CD3, CD20, and CD68 are involved in detection of tumor cell.
How is detection of tumor cell studied?
It is studied using cell-free DNA fragmentomics, histopathologic evaluation, immunohistochemistry, and cell line establishment.
Why is detection of tumor cell important in cancer?
It is the first step in immune surveillance and early diagnosis, enabling detection of malignant and premalignant tumors before they progress.
What diseases are associated with detection of tumor cell?
Diseases include neurofibromatosis 1, malignant peripheral nerve sheath tumors, giant cell-rich tumors of bone, and ovarian follicle cysts.
Can CRISPR be used to study detection of tumor cell?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can dissect the molecular mechanisms of GO:0002355.
What is the role of ALDH1 in detection of tumor cell?
ALDH1 is a tumor stem cell marker expressed in benign epithelial odontogenic lesions and may influence detection thresholds.
How do immune cells detect tumor cells?
Immune cells such as T cells, B cells, and macrophages recognize tumor-derived signals in the microenvironment, as seen in cutaneous neurofibromas.
What is cell-free DNA fragmentomics?
It is a method that analyzes circulating DNA fragmentation patterns to detect tumor-derived signals, used for early detection of peripheral nerve tumors.
What model systems are available for detection of tumor cell research?
Models include knockout cell lines, point mutation knock-ins, overexpression lines, and co-culture systems with immune cells.
Conclusion
Detection of tumor cell (GO:0002355) is a fundamental biological process that underlies immune surveillance and early cancer diagnosis. Its molecular mechanisms involve the receipt of tumor-derived stimuli and their conversion into signals that can be measured diagnostically or functionally. Research into this process has been advanced by cell-free DNA fragmentomics, histopathologic evaluation, and the establishment of tumor cell lines. Understanding the genes and pathways involved, such as NF1, CDKN2A, TP53, and ALDH1, is essential for developing early detection strategies and targeted therapies. CRISPR-based models offer powerful tools to dissect these mechanisms and identify novel regulators of tumor cell detection.
References
- 1. Sundby RT et al.. 2024. Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.. Clin Cancer Res 30(19):4363-4376 PMID: 39093127
- 2. Miettinen MM et al.. 2017. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview.. Hum Pathol 67:1-10 PMID: 28551330
- 3. Hartmann W et al.. 2021. Giant Cell-Rich Tumors of Bone.. Surg Pathol Clin 14(4):695-706 PMID: 34742488
- 4. da Trindade GA et al.. 2022. Expression of a Tumor Stem Cell Marker (Aldehyde Dehydrogenase 1-ALDH1) in Benign Epithelial Odontogenic Lesions.. Head Neck Pathol 16(3):785-791 PMID: 35349099
- 5. Zhang X et al.. 2024. Establishment and characterization of a recurrent malignant peripheral nerve sheath tumor cell line: RsNF.. Hum Cell 37(1):345-355 PMID: 37938540
- 6. McMullen ER et al.. 2022. Large Ovarian Follicle Cyst: Benign Mimic of Cystic Adult Granulosa Cell Tumor.. Int J Gynecol Pathol 41(3):289-291 PMID: 34166278
- 7. Kallionpää RA et al.. 2024. Characterization of Immune Cell Populations of Cutaneous Neurofibromas in Neurofibromatosis 1.. Lab Invest 104(1):100285 PMID: 37949359
- 8. Datta NK et al.. 2023. Management of the Hand Tumors.. Mymensingh Med J 32(1):135-143 PMID: 36594313
